Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril

A E Gliddon, C J Doré, C M Black, Neil J McHugh, R Moots, C P Denton, A Herrick, T Barnes, J Camilleri, K Chakravarty, P Emery, B Griffiths, N D Hopkinson, P Hickling, P Lanyon, C Laversuch, T Lawson, R Mallya, M Nisar, C Rhys-DillonT Sheeran, P J Maddison

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Administration of quinapril for up to 3 years had no demonstrable effects on the occurrence of upper limb digital ulcers or on other vascular manifestations of lcSSc in this patient population.
Original languageEnglish
Pages (from-to)3837-46
Number of pages10
JournalArthritis & Rheumatism
Volume56
Issue number11
DOIs
Publication statusPublished - 2007

Fingerprint Dive into the research topics of 'Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril'. Together they form a unique fingerprint.

  • Cite this

    Gliddon, A. E., Doré, C. J., Black, C. M., McHugh, N. J., Moots, R., Denton, C. P., Herrick, A., Barnes, T., Camilleri, J., Chakravarty, K., Emery, P., Griffiths, B., Hopkinson, N. D., Hickling, P., Lanyon, P., Laversuch, C., Lawson, T., Mallya, R., Nisar, M., ... Maddison, P. J. (2007). Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis & Rheumatism, 56(11), 3837-46. https://doi.org/10.1002/art.22965